Nuveen Asset Management LLC Has $6.25 Million Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Nuveen Asset Management LLC increased its position in shares of CareDx, Inc (NASDAQ:CDNA – Get Rating) by 1.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 366,924 shares of the company’s stock after acquiring an additional 6,729 shares during the quarter. Nuveen Asset Management LLC’s holdings in CareDx were worth $6,245,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Teacher Retirement System of Texas bought a new stake in CareDx in the third quarter valued at about $297,000. Shell Asset Management Co. increased its holdings in CareDx by 152.9% in the second quarter. Shell Asset Management Co. now owns 5,953 shares of the company’s stock valued at $128,000 after purchasing an additional 3,599 shares during the last quarter. Great West Life Assurance Co. Can bought a new stake in CareDx in the third quarter valued at about $208,000. Walleye Capital LLC bought a new stake in CareDx in the second quarter valued at about $781,000. Finally, AlphaCrest Capital Management LLC increased its holdings in CareDx by 207.8% in the second quarter. AlphaCrest Capital Management LLC now owns 34,168 shares of the company’s stock valued at $734,000 after purchasing an additional 23,067 shares during the last quarter.

Insider Transactions at CareDx

In other news, insider Reginald Seeto sold 2,819 shares of the company’s stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $17.15, for a total transaction of $48,345.85. Following the completion of the transaction, the insider now directly owns 575,803 shares of the company’s stock, valued at $9,875,021.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Peter Maag sold 3,269 shares of the stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $15.75, for a total transaction of $51,486.75. Following the completion of the transaction, the director now directly owns 295,468 shares of the company’s stock, valued at $4,653,621. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Reginald Seeto sold 2,819 shares of the stock in a transaction that occurred on Thursday, February 2nd. The shares were sold at an average price of $17.15, for a total value of $48,345.85. Following the transaction, the insider now directly owns 575,803 shares of the company’s stock, valued at $9,875,021.45. The disclosure for this sale can be found here. Insiders sold 30,888 shares of company stock valued at $492,669 over the last three months. Company insiders own 4.60% of the company’s stock.

CareDx Price Performance

CDNA stock opened at $9.53 on Monday. The stock has a market capitalization of $511.48 million, a P/E ratio of -6.62 and a beta of 1.03. The business has a 50-day moving average of $13.91 and a 200-day moving average of $15.11. CareDx, Inc has a fifty-two week low of $8.10 and a fifty-two week high of $41.50.

Analyst Ratings Changes

CDNA has been the subject of a number of recent analyst reports. BTIG Research dropped their price objective on CareDx from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, February 28th. The Goldman Sachs Group lowered their price target on CareDx from $25.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, March 7th. Stephens downgraded CareDx from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $19.00 to $9.00 in a report on Tuesday, March 7th. StockNews.com upgraded CareDx from a “sell” rating to a “hold” rating in a report on Wednesday, March 8th. Finally, Raymond James downgraded CareDx from a “strong-buy” rating to a “market perform” rating and set a $24.00 price target for the company. in a report on Friday, March 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, CareDx presently has a consensus rating of “Hold” and a consensus target price of $16.00.

About CareDx

(Get Rating)

CareDx, Inc operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.